Leva Capital
VC Fund
Toronto, Canada
Leva Capital is a VC fund in Toronto focused on Health Care and Medical. Leva Capital invests in privately owned businesses within the healthcare sector in Canada, from startups to medium sized companies.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Leva Capital invests in
Stages Leva Capital invests in
Countries Leva Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $1.9M–$3.6M
- Pre-Seed
- $893k–$5M
- Series A
- $12M–$15M
Investment Focus
Industry
- Health Care 7 (58%)
- Medical 4 (33%)
- Biotechnology 2 (17%)
- Medical Device 2 (17%)
- Personal Health 2 (17%)
Stage
- Seed 3 (25%)
- Pre-Seed 3 (25%)
- Series A 2 (17%)
- Angel 1 (8%)
- Funding Round 1 (8%)
Country
- Canada 7 (58%)
- United States 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Eddie Gobran
Managing General Partner
|
Managing General Partner | Total investments: 2 | Find email | |
Matt Girgis
Co-Founder
|
Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Eli
|
Eli empowers women to understand their body and the transitions it goes through every day, and across life. We develop a device that uses saliva to capture hormone fluctuations at home, and an app that gives women the information they want to own their health decisions. | $12M / Series A / Jun 10, 2025 | |
Northernmost
|
Northernmost is a company that develops machines that protect and transport donated kidneys for transplantation. | $1.9M / Seed / Apr 03, 2025 | |
FluidAI Medical
|
FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $14.6M / Series A / Oct 10, 2023 | |
|
FluidAI Medical
|
FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $15M / Series A / Oct 10, 2023 | |
|
Eli
|
Eli empowers women to understand their body and the transitions it goes through every day, and across life. We develop a device that uses saliva to capture hormone fluctuations at home, and an app that gives women the information they want to own their health decisions. | $3.6M / Seed / Apr 04, 2023 | |
Revalia Bio
|
Revalia Bio develops curative drugs for chronic organ-centered disease. | $5M / Pre-Seed / Mar 01, 2023 | |
LUCID
|
LUCID curates and creates personalized therapeutic music using biometrics, psychometrics, and AI to improve mental health and wellness. | $2.3M / Seed / Aug 12, 2022 | |
|
LUCID
|
LUCID curates and creates personalized therapeutic music using biometrics, psychometrics, and AI to improve mental health and wellness. | $2.5M / Pre-Seed / Aug 12, 2022 | |
|
FluidAI Medical
|
FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $15M / Series A / Mar 03, 2022 | |
ManagingLife
|
ManagingLife's industry-leading digital health solution, Manage My Pain, helps patients and doctors better measure, monitor, and manage pain. Manage My Pain is a digital pain treatment companion with clinical validation and has one of the largest datasets that includes over 5M patient-reported pain outcomes from over 125,000 users from 130countries. Built into Manage My Pain is Solace, a first-of-its-kind AI companion that delivers real-time, evidence-based pain psychology support - which showed significant improvements in people who interacted with it for just 30 minutes.Manage My Pain is the leading pain app on the market, and has been licensed by hospitals and insurers across North America. Manage My Pain improves patient outcomes, reduces medical spend, and shortens disability claims. | $1.3M / Feb 09, 2022 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Leva Capital invest in?
Leva Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 12 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Leva Capital's check size?
Leva Capital typically joins rounds of $1.9M–$3.6M at Seed, $893k–$5M at Pre-Seed and $12M–$15M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Leva Capital participates in.
How do I contact Leva Capital?
Public channels for Leva Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Leva Capital?
The team at Leva Capital includes Eddie Gobran (Managing General Partner) and Matt Girgis (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
